CSCI.TO COSCIENS BIOPHARMA INC
$7.65▲ +0.53%
Healthcare
Other
Volume 2.0K
Avg Volume (10D) 340
Key Metrics & Fundamentals
Market Cap
$8.12M
P/E Ratio
–
Div Yield
–%
52W Range
7.00 - 39.60
% vs 50 MA
-14.40%
% vs 200 MA
-61.99%
RSI-14
41.8
MACD Histogram
+0.2500
Beta (1Y vs SPY)
0.33
Free Cash Flow
-$2.18M
Gross Rev
$1.89M
Gross Profit
$793,000
EBITDA
-$361,000
COGS
$1.10M
Operating Exp
$1.52M
Operating Income
-$730,000
EBIT
-$730,000
Pretax Income
-$183,000
Net Income
$10.76M
EPS (Diluted)
8.70
Price & Volume History
Loading chart…
Recent News
Canadian Investment Regulatory Organization Trade Resumption - CSCI
CNW Group · Sep 11, 2026 12:10 PM
COSCIENS Biopharma Acquires Pharma Tech Business Nualtis For $15 Million Cash
MT Newswires · Sep 10, 2026 8:43 PM
COSCIENS ACQUIRES NUALTIS CORP.
GlobeNewswire · Sep 10, 2026 8:15 PM
Canadian Investment Regulatory Organization Trading Halt - CSCI
CNW Group · Sep 10, 2026 7:32 PM
COSCIENS Biopharma: Q2 Earnings Snapshot
Associated Press · Aug 11, 2026 9:53 PM
COSCIENS Biopharma Inc. Reports Q2 2026 Results
GlobeNewswire · Aug 11, 2026 9:30 PM
COSCIENS Biopharma Completes Share Capital Amendment
MT Newswires · Jul 3, 2026 1:30 PM
COSCIENS Biopharma Inc. Completes Share Capital Amendment
GlobeNewswire · Jul 3, 2026 12:30 PM
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
GlobeNewswire · Jun 23, 2026 12:16 AM
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
GlobeNewswire · Jun 18, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
Mar 2026
See CSCI.TO's money flow as a full page
Social Sentiment
No Reddit posts found for CSCI.TO.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.